ScinoPharm Taiwan Ltd
TWSE:1789
Relative Value
The Relative Value of one ScinoPharm Taiwan Ltd stock under the Base Case scenario is 18.63 TWD. Compared to the current market price of 28.4 TWD, ScinoPharm Taiwan Ltd is Overvalued by 34%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
ScinoPharm Taiwan Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
TW |
ScinoPharm Taiwan Ltd
TWSE:1789
|
22.5B TWD | 7 | 78.2 | 24.6 | 60.8 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
698.5B USD | 19.4 | 113.8 | 55.8 | 63.5 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.3 | 33.1 | 36.1 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
359.3B USD | 4.2 | 9.3 | 11.5 | 15 | ||
US |
Merck & Co Inc
NYSE:MRK
|
322.8B USD | 5.3 | 140 | 33.3 | 52.8 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.3 | 140.7 | 225.6 | ||
CH |
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.3 | 13.4 | 9.8 | 16.2 | ||
CH |
Roche Holding AG
SIX:ROG
|
173.2B CHF | 3 | 15.1 | 8.6 | 10.2 | ||
US |
Pfizer Inc
NYSE:PFE
|
157B USD | 2.9 | -508.1 | 12.6 | 20.1 |